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Abstract
Background: Accurate determination of the predictive markers human epidermal growth factor receptor 2
(HER2/ERBB2), estrogen receptor (ER/ESR1), progesterone receptor (PgR/PGR), and marker of proliferation Ki67
(MKI67) is indispensable for therapeutic decision making in early breast cancer. In this multicenter prospective
study, we addressed the issue of inter- and intrasite reproducibility using the recently developed reverse
transcription-quantitative real-time polymerase chain reaction-based MammaTyper® test.
Methods: Ten international pathology institutions participated in this study and determined messenger RNA
expression levels of ERBB2, ESR1, PGR, and MKI67 in both centrally and locally extracted RNA from formalin-fixed,
paraffin-embedded breast cancer specimens with the MammaTyper® test. Samples were measured repeatedly on
different days within the local laboratories, and reproducibility was assessed by means of variance component
analysis, Fleiss’ kappa statistics, and interclass correlation coefficients (ICCs).
Results: Total variations in measurements of centrally and locally prepared RNA extracts were comparable; therefore,
statistical analyses were performed on the complete dataset. Intersite reproducibility showed total SDs between 0.21
and 0.44 for the quantitative single-marker assessments, resulting in ICC values of 0.980–0.998, demonstrating excellent
agreement of quantitative measurements. Also, the reproducibility of binary single-marker results (positive/negative), as
well as the molecular subtype agreement, was almost perfect with kappa values ranging from 0.90 to 1.00.
Conclusions: On the basis of these data, the MammaTyper® has the potential to substantially improve the current
standards of breast cancer diagnostics by providing a highly precise and reproducible quantitative assessment of the
established breast cancer biomarkers and molecular subtypes in a decentralized workup.
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Background
In contemporary clinical management of patients with
breast cancer, prognostications and therapeutic decisions
are based on the assessment of clinicopathological factors
as well as on the expression status of biomarkers with
established clinical validity (i.e., human epidermal growth
factor receptor 2 [HER2]; estrogen receptor [ER]; progester-
one receptor [PgR]; and Ki67, a marker of cell proliferation)
[1, 2]. Currently, the most commonly applied method for
the determination of these four markers is immunohisto-
chemistry (IHC), which allows for the semiquantitative as-
sessment of the protein expression levels on histological
slides [3, 4]. For HER2, an additional analysis of the
amplification status of the corresponding gene ERBB2
by fluorescence in situ hybridization (FISH), chromogenic
in situ hybridization (CISH), or silver in situ hybridization
(SISH) can also be applied in selected cases. The quality of
the determination of these markers in terms of accuracy
and reproducibility is essential for effective therapeutic in-
terventions. However, the inter- and intraobserver vari-
ability of IHC is of concern [3–9]. For HER2, ER, and PgR,
several studies have reported discrepancies of up to 20%
[5–7], but most prominent and challenging is the incon-
sistency regarding Ki67 [8, 9]. Ki67 is a marker of the pro-
liferative activity of the tumor cells and thereby carries
valuable prognostic information [10–12]. In addition, Ki67
may have a direct impact on therapeutic decisions by
assisting in the distinction between luminal A and luminal
B breast cancer and therefore may aid in the selection of
cytotoxic chemotherapy in addition to endocrine treat-
ment [2, 13]. The variability in Ki67 is due mainly to the
subjectivity of the visual estimation method and the choice
of areas of evaluation on the histological slides and, to a
lesser extent, the technical variations in the IHC staining
process [9, 14]. Efforts to standardize Ki67 scoring resulted
in considerable improvements, but interobserver agree-
ment is still unsatisfactory [15, 16]. In addition, implemen-
tation of these methodological advances in clinical routine
laboratories is challenging, and clinical validity of the new
methods remains to be shown. For these reasons, the Ki67
determined by IHC is not currently included in the
American Society of Clinical Oncology/College of Ameri-
can Pathologists guidelines for routine clinical use [1, 17].
There remains an urgent need for alternative, more ro-
bust, standardized, and precise assays with proven analyt-
ical and clinical validity for Ki67, HER2, ER, and PgR in
routine breast cancer diagnostics [17, 18].
The MammaTyper® (BioNTech Diagnostics, Mainz,
Germany) is a novel CE-marked in vitro diagnostic test
that quantifies the messenger RNA (mRNA) expression
of the four key marker genes ERBB2, ESR1, PGR, and
MKI67 on the basis of reverse transcription-quantitative
real-time polymerase chain reaction (RT-qPCR), which
differs from the currently applied standard of protein-
based semiquantitative assessment by IHC. The main
goal in using this technology is to provide a precise and
reproducible assessment of the four biomarkers. Similarly
to IHC, the MammaTyper® test can be integrated into the
local laboratory setup because it supports analysis on widely
accessible qPCR platforms using total RNA extracted
from clinical routine formalin-fixed, paraffin-embedded
(FFPE) breast cancer samples from resections or core
needle biopsies.
In this study, we assessed the precision of the Mam-
maTyper® test with a focus on reproducibility [19]. We
adopted a multicenter design to fully evaluate the inter-
and intrasite components of precision as well as other
sources of imprecision, including preanalytical factors.
Ten international pathology institutions, all with expert-
level background in the field of breast cancer diagnos-
tics, participated in the study. Each site carried out the
same technical procedures according to a predefined
study plan based on the EP05-A3 guideline for precision
evaluation of quantitative measurement methods issued
by the Clinical & Laboratory Standards Institute [20]. To
our knowledge, a similar study has not been conducted
to date.
Methods
Study objectives
The precision (reproducibility) of the MammaTyper® test
was evaluated on multiple levels according to the follow-
ing parameter definitions:
1. Intermediate precision, here also referred as interrun
precision, as the variability of quantitative results
across repeated measurements over several days by
the same operator, in the same laboratory, and using
the same instrument; this parameter also included
repeatability, the variance component due to simple
replicates (intrarun)
2. Intersite reproducibility, as the most comprehensive
demonstration of precision, including the variability
introduced by different laboratories, operators, and
instruments
3. Preanalytical and lot-to-lot variability
4. Agreement of binary single-marker results and
subtypes
5. Interclass correlation coefficient (ICC) as the
agreement of quantitative results
Study design
A prospective, two-stage study was designed with the
participation of ten international pathology institutions
(see authors’ affiliations 1–9 and 14). Prior to the study
start, one operator per site was trained on the correct
use of the preanalytical RNA extraction kit RNXtract®
(BioNTech Diagnostics) and the MammaTyper® test within
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a 2-day standard training phase carried out by the manufac-
turer. This training also included qualification of the local
qPCR instrument for use with the MammaTyper®, which in
this study was the LightCycler® 480 instrument II (Roche
Molecular Diagnostics, Pleasanton, CA, USA). The training
was followed by a familiarization period consisting of at
least four MammaTyper® runs on 3–4 days using BioN-
Tech Diagnostics’ reference material, carried out by the
operator without supervision. During the study, each
site performed repeated MammaTyper® measurements
on different days according to a predefined study plan
using RNA extracts from clinical FFPE breast cancer
tissues. The same MammaTyper® lot was used at all
sites, and only one site repeated study arm 1 using a
second lot of MammaTyper®. The study comprised
8 days in total (consecutive or nonconsecutive days), as
illustrated in the study design (Fig. 1).
Study arm 1
RNA was extracted at a central laboratory (BioNTech
Diagnostics), and eight different RNA pools, each con-
taining RNA from a single tumor sample, were provided
as single-use aliquots to the study sites (samples 1–8).
Samples were measured repeatedly on 4 different days
using MammaTyper®.
Study arm 2
Ten-micrometer sections of 16 FFPE tissue samples from
different breast tumors (samples 9–24) were provided to
each study site for local RNA extraction using RNXtract®.
After extraction, each RNA eluate was split into three
single-use aliquots for repeated MammaTyper® measure-
ments on 3 different days.
Samples
The samples used in the study were prepared from
clinical FFPE breast cancer tissue blocks by BioNTech
Diagnostics and were distributed to study sites as RNA
aliquots (samples 1–8) or 10-μm FFPE whole-tissue sec-
tions (samples 9–24). The 24 FFPE tissue samples were se-
lected from a series of clinical routine breast cancer cases
(n = 43) kindly provided by PSi. A summary of the clinico-
pathological characteristics of these patient samples is
given in Additional file 1: Table S1. The use of archived
samples was approved by the ethics committee of the Uni-
versity of Heidelberg (206/2005). Patient informed consent
(and a specific approval for this study) was not necessary,
because the ethics approval covers the use of samples for
retrospective analysis. The selection process was based on
sample validity (RNA amount) and ERBB2, ESR1, PGR,
and MKI67 marker expression obtained using the Mam-
maTyper®. Different histological subtypes such as ductal,
lobular, tubular, and micropapillary breast carcinomas
were included in the cohort. To encompass the entire
range of clinically anticipated expression levels, six sam-
ples were selected for each marker equally distributed
from the lowest to the highest expression value (sextiles),
including values close to the cutoff. From among the
selected 24 FFPE tissue samples, 8 were chosen for
preparation of the RNA pools; the other 16 were used
for preparation of the FFPE tissue sections. Nineteen
consecutive 10-μm sections were prepared per paraffin
block, and homogeneity of the sections was ensured in
a prequalification process by MammaTyper® analysis of
the first, middle, and last sections (Additional file 2:
Figure S1).
RNA extraction
Total RNA was purified from 10-μm FFPE tissue sections
using the paramagnetic particle-based RNXtract® RNA Ex-
traction Kit (reference 90040; BioNTech Diagnostics
GmbH) according to the manufacturer’s instructions.
The RNXtract® kit has been validated as a preanalytical
RNA extraction method for the MammaTyper® by the
manufacturer.
MammaTyper® test
The MammaTyper® (reference 90020; BioNTech Diagnos-
tics GmbH) is a molecular in vitro diagnostic RT-qPCR test
for the quantitative detection of the mRNA expression sta-
tus of the genes ERBB2, ESR1, PGR, and MKI67 in human
FFPE breast cancer tissue from resection or core needle
biopsies with at least 20% tumor cell content using
whole-tissue sections without macrodissection. Primary
analysis outputs are the normalized, quantitative single-
Fig. 1 Study design. *One site measured additionally a second set
of samples 1–8 using a second lot of MammaTyper®. FFPE
Formalin-fixed, paraffin-embedded
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marker results given as 40−ΔΔCq (quantification cycle)
values on a continuous scale [21]. The test also provides
the status of each marker as a binary category (positive or
negative) based on clinically validated marker- and device-
specific cutoff values. The combination of the four binary
single-marker results can be further translated into the
molecular subtype of the given breast cancer sample
according to the St. Gallen classification [2] (i.e. luminal
A-like, luminal B-like [HER2-negative], luminal B-like
[HER2-positive], HER2-positive [nonluminal], and triple-
negative [ductal]). The MammaTyper® test was performed
according to the Instructions for Use 150528-90020 revi-
sion 3.0, applying the following cutoffs for the LightCycler®
480 II instrument [40−ΔΔCq]: ERBB2 = 41.10, ESR1 = 38.00,
PGR = 35.50, and MKI67 = 35.50.
Statistical analysis
The results were analyzed according to a predefined
statistical analysis plan using SAS version 9.4 software
(SAS Institute, Cary, NC, USA). The number of mea-
surements (sample size) of the study was determined
using simulations to achieve predefined levels of uncer-
tainty using results of a previous method validation [21].
On each study day, exported raw Cq values were directly
transferred by the operator to the statistician. To reflect
a realistic estimate of the test precision, statistical out-
liers were not excluded from the analyses.
The precision of the quantitative single-marker assess-
ments (40−ΔΔCq values) was estimated by a random effects
model II analysis of variance (ANOVA) with site as a ran-
dom factor [20]. Because the variability does not depend
on 40−ΔΔCq values, the sample was also included as a (triv-
ial) random factor in the model, which allows averaging of
the variance components over the samples:
1. The intermediate precision referring to interrun/day
SD is obtained as the residual SD in the ANOVA.
2. The reproducibility was calculated as the intersite
SD summarizing the condition of different sites,
operators, and instruments. The total SD is also
presented, calculated as the square root of the sum
of residual and intersite variance components. Because
the total SD is the precision as experienced in clinical
practice, we decided to report this parameter as the
main result as a conservative approach.
3. The variance introduced by a different
MammaTyper® lot obtained in a separate experiment
was given as the interlot SD.
4. Agreement of the categorical marker results and the
breast cancer biological subtypes across all sites was
evaluated using Fleiss’ kappa statistics [22].
According to the method of Landis and Koch [23],
the strength of the agreement was defined as
follows: kappa < 0.00 = poor, 0.00–0.20 = slight,
0.21–0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80
substantial, and 0.81–1.00 = almost perfect.
5. The ICC was estimated for the continuous scaled
quantitative marker results and was used to evaluate
the reproducibility and intermediate precision in
relationship with the intersample variance using the
approach proposed by Eliasziw et al. [24]. Thus, and
different from the kappa statistic, the ICC determines
the agreement of measured quantitative values over
the whole measurement range, independent of any
cutoff point [25]. The agreement is generally
interpreted as follows: ICC < 0.40 = poor, 0.40–
0.74 = fair to good, and 0.75–1.00 = excellent [26].
More stringent thresholds were recommended by
Kirkegaard et al. [25] for IHC assessments, with an
ICC level of 0.7 regarded as the minimum
acceptable standard, 0.8 as good, and ≥0.9 as
excellent. The latter thresholds were applied in
this study.
In a final analysis, kappa and ICC values were simu-
lated in a larger sample cohort using quantitative data
from 769 breast cancer cases of the FinHer trial that had
been measured previously by MammaTyper® [27]. ICC
values were calculated using the intersample variance of
the larger cohort along with the intersite and residual
variance of the present study. To estimate the kappa
values for this cohort, 1000 simulated pairs of datasets
were created by adding random noise to the 40−ΔΔCq
values according to the marker-specific total variance
observed in this study. For each pair (2 × 769 values),
kappa values for binary marker results and subtypes
were calculated, resulting in 1000 kappa values, of which
the median kappa as well as the 2.5% and 97.5% percen-
tiles are reported.
Results
Intermediate precision
On the basis of MammaTyper® measurements of study
arm 1 (Fig. 1), quantitative single-marker results were
obtained as 40−ΔΔCq values for ERBB2, ESR1, PGR, and
MKI67 and are presented in Fig. 2 as box plots for each
marker, sample, and study site. The intermediate preci-
sion for each marker at the individual site was computed
over all samples, presented as interrun SD (Fig. 2, graphs
at the bottom).
Intersite reproducibility
As indicated by the side-by-side box plots in Fig. 2, the
40−ΔΔCq quantitative single-marker results of each indi-
vidual sample were highly consistent across all ten study
sites. The total SD of the measurements of the eight
centrally extracted RNA samples (samples 1–8) was as
low as 0.18 Cq for PGR, 0.29 Cq for ERBB2 and MKI67,
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Fig. 2 Box plots depicting inter- and intrasite reproducibility. The box plots represent the distribution of the four MammaTyper® measurements of
the eight centrally extracted RNA samples for each marker at the ten different study sites A–J (study arm 1). The box plots indicate the median
40−ΔΔCq values by the horizontal line dividing the boxes, the first and third quartiles by the lower and upper borders of the boxes, and the
minimum and maximum values by the whiskers. The graphs at the bottom show the interrun SD over all samples for each marker at the
respective site, as well as the corresponding 95% CI. ERBB2 (HER2) Human epidermal growth factor receptor 2, ESR1 (ER) Estrogen receptor,
MKI67 Marker of proliferation Ki67, PGR (PgR) Progesterone receptor
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and 0.44 Cq for ESR1 (Table 1, upper panel). As demon-
strated by the variance component analysis, the factor
site (intersite SD) had less impact on the total impreci-
sion (total SD) than the interrun/day variability within
one laboratory (residual SD) (Table 1, upper panel).
Intersite reproducibility including preanalytical variances
The total variance of marker results (40−ΔΔCq values) in
the self-extracted samples (study arm 2, samples 9–24) was
almost identical to the variance seen for the RNA pool ali-
quots (samples 1–8) (Table 1, middle panel). There was no
additional variance or bias introduced by RNA extraction
at local sites. Therefore, the intersite reproducibility was
again computed on the whole sample set (samples 1–24),
leading to a similar approximation of the total vari-
ability of single-marker 40−ΔΔCq assessments with SDs
between 0.21 and 0.44 Cq (Table 1, lower panel). Per-
forming the analysis of the eight RNA pool samples
with a different MammaTyper® lot resulted in compar-
able quantitative values (Additional file 3: Figure S2).
The interlot SD was almost completely covered by the
existing interrun/day variability (residual SD), and its
impact on the total variance was negligible (Additional
file 4: Table S2). Individual laboratory deviations for
all samples are also shown with Bland-Altman plots
(Fig. 3). The average deviation at the respective site
was in all cases close to zero, with values ranging from
Cq −0.13 to 0.16 for ERBB2, −0.11 to 0.20 for ESR1, −0.15
to 0.19 for PGR, and −0.22 to 0.31 forMKI67.
Binary single-marker and subtype agreement
The binary single-marker results (positive/negative) for
all measurements at the ten sites are displayed as counts
for each sample in Table 2, revealing a very high concord-
ance. The 24 samples showed 100% concordance for
ERBB2 and for PGR and ESR1 an equivocal assignment in
only one and two samples, respectively. These cases exhib-
ited a marker expression level near the cutoff, as indicated
by the distance to cutoff value (Table 2). This also ex-
plained the divergent measurements seen for MKI67,
which biologically exhibits more samples near the cutoff
because of its continuous distribution [28]. Nevertheless,
MKI67 showed a high agreement because for most dis-
crepant cases only 1 of 30 determinations was classified
differently (Table 2). Calculating the overall agreement of
the categorical marker assessments resulted in kappa
values of 1.00, 0.91, 0.94, and 0.94 for ERBB2, ESR1, PGR,
and MKI67, respectively. Corresponding subtype assess-
ments resulted in an almost perfect agreement with a
kappa value of 0.90 (Table 3). Discrepancies were observed
for example for the luminal A-like and luminal B-like
(HER2-negative) subtype, where discrimination using St.
Gallen guidelines relies on MKI67 marker expression [2],
which for the discrepant cases was very close to the cutoff
(as described above).
Intra- and interclass correlation
ICC estimates of all markers were between 0.976
and 0.996 for the intralaboratory assessment
(ICC_intra), and between 0.980 and 0.998 for the
intersite reproducibility (ICC_inter) (Table 4, upper
panel), reflecting excellent agreement of the quanti-
tative data. To exclude any effect of the sample se-
lection on ICC results, the ICCs were again
computed using the intersample variance observed in
the 769 breast cancer cases of the FinHer trial [27]
Table 1 Intersite reproducibility of centrally (samples 1–8) and locally (samples 9–24) extracted RNA samples as total SD, as well as
intersite and residual SD (quantification cycle values)
Analyte Intersite Residual Total
SD 95% CI SD 95% CI SD
RNA pools Samples 1–8 ERBB2 0.16 0.12–0.21 0.24 0.22–0.27 0.29
ESR1 0.18 0.13–0.29 0.40 0.37–0.44 0.44
PGR 0.09 0.07–0.13 0.16 0.15–0.17 0.18
MKI67 0.21 0.17–0.26 0.21 0.19–0.23 0.29
Self-extracted RNAs Samples 9–24 ERBB2 0.22 0.19–0.26 0.23 0.21–0.24 0.31
ESR1 0.25 0.20–0.31 0.36 0.34–0.39 0.44
PGR 0.12 0.10–0.16 0.19 0.18–0.20 0.23
MKI67 0.16 0.14–0.20 0.19 0.18–0.21 0.25
RNA pools and self-extracted RNAs Samples 1–24 ERBB2 0.20 0.17–0.23 0.23 0.22–0.25 0.31
ESR1 0.22 0.19–0.27 0.38 0.36–0.40 0.44
PGR 0.11 0.10–0.14 0.18 0.17–0.19 0.21
MKI67 0.18 0.16–0.21 0.20 0.19–0.21 0.27
Abbreviations: ERBB2 (HER2) Human epidermal growth factor receptor 2, ESR1 (ER) Estrogen receptor, MKI67 Marker of proliferation Ki67, PGR (PgR)
Progesterone receptor
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along with the intersite and residual variance ex-
tracted from the present reproducibility study. The
marker-specific ICCs in this analysis were nearly
identical (Table 4, lower panel).
Finally, the kappa values were simulated in this larger
sample cohort and were found to be comparable to the
ones observed in the smaller sample size of the present
study (Table 4, lower panel).
Discussion
This study addressed the question whether the recently
developed molecular in vitro diagnostic MammaTyper®
Fig. 3 Bland-Altman plots representing inter- and intrasite reproducibility. Bland-Altman plots show the differences of the measured 40−ΔΔCq values per sam-
ple, site, and marker (y-axis) against the respective mean over all measurements (sites and days) (x-axis). The 24 samples are represented by either 4 or 3 mea-
surements for the centrally extracted (study arm 1) or self-extracted (study arm 2) RNA samples, respectively. The average deviation of measurements at the
respective site is indicated by the dashed horizontal line. The continuous vertical line indicates the marker-specific cutoff. ERBB2 (HER2) Human epidermal growth
factor receptor 2, ESR1 (ER) Estrogen receptor, MKI67 Marker of proliferation Ki67, PGR (PgR) Progesterone receptor. a-j correspond to the ten study sites
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test could improve the reproducibility of the assessment
of the four key routine breast cancer biomarkers ERBB2
(HER2), ESR1 (ER), PGR (PgR), and MKI67 (Ki67). The
routine diagnostic assessment of these markers, as well
as the corresponding subtyping, is currently performed
by semiquantitative IHC and FISH, CISH, and SISH
assays [1–4]. IHC assays suffer from considerable in-
ter- and intralaboratory variability, which particularly
applies to the assessment of the valuable biomarker
Ki67 [8, 9, 15, 16]. Therefore, it is of importance that
new technologies carrying the potential for more accurate,
reliable, and precise analysis of Ki67 expression are
brought under consideration to overcome the persisting
inconsistencies [17, 18].
In this multicenter study, we demonstrated that Mamma-
Typer® shows excellent inter- and intralaboratory precision,
both for the continuous quantitative single-marker mea-
surements (40−ΔΔCq values) and for the categorical positive/
negative status and the breast cancer molecular subtype
classification. These data therefore confirm the high analyt-
ical performance of the MammaTyper® that was previ-
ously reported in the original technical validation of the
test [21] but was shown in this study in a more com-
prehensive and challenging methodological setting. In
our study, ten different laboratories were able to gener-
ate consistent and highly concordant test results after
an initial training and a relatively short familiarization
period. Overall, the test results were found to be inde-
pendent of the preanalytical process and not influenced
by the MammaTyper® lot. The source of imprecision of
the quantitative measurements was related mainly to
the general run-to-run variability rather than to the
Table 2 Binary single-marker agreements as positive/negative counts, and corresponding kappa values (distance of mean 40−ΔΔCq
value to marker-specific cutoff is shown for each sample)
ERBB2 ESR1 PGR MKI67
Sample Counts Distance
to cutoff
(Cq)
Counts Distance
to cutoff
(Cq)
Counts Distance
to cutoff
(Cq)
Counts Distance
to cutoff
(Cq)
Negative Positive Negative Positive Negative Positive Negative Positive
1 40 0 −1.1 0 40 1.5 0 40 3.2 40 0 −3.2
2 40 0 −1.1 0 40 1.7 0 40 1.8 40 0 −0.8
3 0 40 0.6 0 40 1.9 0 40 2.5 0 40 0.8
4 40 0 −1.2 0 40 3.0 0 40 4.6 0 40 0.7
5 40 0 −1.9 0 40 1.6 0 40 5.6 0 40 0.6
6 40 0 −2.9 0 40 1.4 0 40 6.0 0 40 0.6
7 40 0 −3.2 40 0 −4.0 40 0 −3.0 0 40 2.2
8 0 40 1.7 12 28 0.2 0 40 2.9 0 40 1.3
9 0 30 1.3 30 0 −3.2 30 0 −2.3 0 30 1.1
10 0 30 3.1 30 0 −2.0 30 0 −1.7 0 30 1.5
11 30 0 −1.6 0 30 2.1 0 30 4.9 4 26 0.2
12 30 0 −1.8 0 30 2.7 0 30 4.7 0 30 1.1
13 30 0 −1.8 0 30 2.4 0 30 4.6 1 29 0.4
14 30 0 −2.0 0 30 1.4 0 30 3.2 30 0 −0.8
15 30 0 −1.3 0 30 1.1 0 30 1.0 29 1 −1.2
16 29 0 −1.5 0 29 2.5 0 29 2.9 0 29 0.7
17 30 0 −1.1 0 30 1.4 0 30 0.8 0 30 1.1
18 30 0 −1.3 0 30 2.5 0 30 4.2 30 0 −1.2
19 30 0 −1.5 0 30 2.8 0 30 2.8 1 29 0.4
20 30 0 −2.6 30 0 −0.9 0 30 3.3 29 1 −0.6
21 30 0 −2.8 20 10 0.0 0 30 3.4 29 1 −0.5
22 30 0 −3.1 30 0 −3.4 30 0 −3.1 0 30 2.1
23 30 0 −3.1 30 0 −2.3 16 14 0.0 0 30 2.2
24 0 30 1.9 30 0 −5.2 30 0 −3.3 1 29 0.4
kappa Statistic 1.00 0.91 0.94 0.94
Abbreviations: ERBB2 (HER2) Human epidermal growth factor receptor 2, ESR1 (ER) Estrogen receptor, MKI67 Marker of proliferation Ki67, PGR (PgR)
Progesterone receptor
Boldface values represent summary of measurements
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Table 3 Subtype agreement as counts, and corresponding kappa value
Sample Not defined HER2-positive
(nonluminal)
Luminal B-like
(HER2-positive)
Luminal B-like
(HER2-negative)
Triple-negative (ductal) Luminal A-like
1 0 0 0 0 0 40
2 0 0 0 0 0 40
3 0 0 40 0 0 0
4 0 0 0 40 0 0
5 0 0 0 40 0 0
6 0 0 0 40 0 0
7 0 0 0 0 40 0
8 12 0 28 0 0 0
9 0 30 0 0 0 0
10 0 30 0 0 0 0
11 0 0 0 26 0 4
12 0 0 0 30 0 0
13 0 0 0 29 0 1
14 0 0 0 0 0 30
15 0 0 0 1 0 29
16 0 0 0 29 0 0
17 0 0 0 30 0 0
18 0 0 0 0 0 30
19 0 0 0 29 0 1
20 30 0 0 0 0 0
21 20 0 0 0 0 10
22 0 0 0 0 30 0
23 14 0 0 0 16 0
24 0 30 0 0 0 0
kappa Statistic 0.90
Abbreviations: HER2 Human epidermal growth factor receptor 2
Boldface values represent summary of measurements
Table 4 Interclass correlation coefficient based on depicted variance components, and summary of kappa values
Analyte Intersite variance Intersample variance Residual variance ICC_intra ICC_inter kappa Statistic
ERBB2 0.039 2.886 0.054 0.982 0.987 1.00
ESR1 0.049 5.889 0.144 0.976 0.992 0.91
PGR 0.013 8.279 0.031 0.996 0.998 0.94
MKI67 0.032 1.565 0.039 0.976 0.980 0.94
Subtype N/A 0.90
Analyte Intersite variance
(present study)
Intersample variance
(FinHer data)
Residual variance
(present study)
ICC_intra ICC_inter kappa Statistic
(median)
2.5–97.5%
percentile
ERBB2 0.039 3.723 0.054 0.986 0.990 0.95 0.92–0.97
ESR1 0.049 5.941 0.144 0.977 0.992 0.97 0.96–0.99
PGR 0.013 7.461 0.031 0.996 0.998 0.97 0.96–0.99
MKI67 0.032 1.739 0.039 0.978 0.982 0.85 0.82–0.88
Subtype N/A 0.91 0.89-0.93
Abbreviations: ERBB2 (HER2) Human epidermal growth factor receptor 2, ESR1 (ER) Estrogen receptor, MKI67 Marker of proliferation Ki67, PGR (PgR) Progesterone
receptor, N/A Not applicable
Note: Intersite variance and residual variance are squares of SD presented in lower part of Table 1. The lower panel of this table is a simulated analysis using the
intersample variance of data from the FinHer trial cohort (described in detail in the text)
Boldface values highlight ICC and kappa statistic
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variance introduced by different laboratories. These ob-
servations were in line with the original technical valid-
ation report [21].
The ICC values for all markers were above 0.976,
which signifies excellent agreement of the quantitative
data and suggests improved inter- and intrasite reprodu-
cibility achieved with qPCR compared with what has
been documented previously for IHC [9, 16]. In studies
on IHC reproducibility, the intersite agreement for Ki67
IHC displays an ICC of 0.59, which is below the mini-
mum acceptable standard proposed by Kirkegaard et al.
[9, 25]. Even when standardized Ki67 scoring methods
on centrally stained histological slides were tested, the
interobserver reliability on resection specimens reached
ICCs of only 0.40 to 0.74, with kappa values ranging
from 0.29 to 0.58 [16]. Only training and precise calibra-
tion resulted in better Ki67 assessment on centrally
stained tissue microarray slides (ICC 0.94) or centrally
stained core-cut biopsies using a standardized scoring
method (ICC 0.87), but this process is difficult to imple-
ment in routine clinical practice, and clinically important
discrepancies persisted in the critical range of 10% to
20% Ki67-positive nuclei staining [15, 29]. The chal-
lenges in the standardization of Ki67 assessment include
the variability in the selection of the tumor areas to be
assessed, the technique used for nuclei counting, and
the dilemma of the numerical cutoff for positivity, espe-
cially for large tissue sections [8, 9, 15, 16]. The highly
promising reproducibility of the MammaTyper® was con-
firmed by a simulated analysis using MammaTyper® data
obtained from 769 samples from the FinHer trial cohort
[27], verifying that the study samples were representative
of the whole spectrum of routine clinical samples.
The high values of the various reproducibility metrics
in the present study are a result of both the underlying
high degree of standardization of the MammaTyper® test,
which minimizes the main sources of variability, and the
adaptation of a fully objective assessment method (i.e.,
qPCR). Thus, the MammaTyper® assay has the potential
to overcome the substantial and varying rates of inter-
and intraobserver variability that may occur with IHC.
This applies especially in samples where high-quality IHC
is not readily available for diagnostic purposes. Analytical
validity, such as reproducibility, is a prerequisite for accur-
ate diagnostics, and its formal evaluation is required along
with a test’s clinical performance to allow conclusions on
its potential use in clinical practice [17, 18]. In a previous
clinical performance evaluation study, good concordance
was shown between MammaTyper® single-marker assess-
ments and IHC (or IHC/CISH for HER2), using 769 ar-
chived breast cancer cases available from the FinHer trial
[27]. Only for MKI67 mRNA expression was the correl-
ation moderate, most likely because of the analytical re-
striction of Ki67 IHC. The multivariable analysis revealed
that MKI67 expression assessed by MammaTyper®, but
not Ki67 IHC, was an independent predictor of distant
disease-free survival (DDFS), indicating the superiority of
MammaTyper® compared with IHC with respect to
MKI67/Ki67 determination [27]. Furthermore, this clinical
performance evaluation study demonstrated that the
mRNA-based subtyping by MammaTyper® resulted in
clinically meaningful prognostic and predictive informa-
tion with regard to DDFS, overall survival, and response
to taxane-based chemotherapy in the luminal B-like
(HER2-negative) subtype [27]. These published data
provide evidence for the clinical validity of the test, and
additional clinical performance evaluation studies would
help further strengthen its clinical value for routine ap-
plications. As is true of all molecular assays that use
tissue homogenates, one may also consider low tumor
cell content or high lymphocytic infiltration as poten-
tial sources of error. For MammaTyper®, a minimum
tumor cell content of 20% was required to generate
stable test results when compared with the paired
macrodissected sample [21]. Adjacent nontumor tissue
had no major influence on test results, likely because of
the reduced metabolic activity and low RNA content in
the surrounding tissue compared with the invasive
tumor [30, 31]. As reported previously, nontumor com-
ponents may have a stronger impact on multigene tests
that analyze a recurrence score based on genes with
partially notable expression in normal tissue [32, 33].
Nevertheless, further validations of MammaTyper® on
samples with problematic characteristics (i.e., varying
amounts of ductal carcinoma in situ and lymphocytic
infiltrates) should be envisaged.
The reliable quantification of single-marker expression
by MammaTyper® has the potential to become part of a
predictive marker panel in breast cancer diagnostics with
further refined implications for clinical management.
The expression of the single markers ERBB2, ESR1,
PGR, and MKI67 is obtained on a continuous scale cov-
ering a much broader dynamic range (up to 5 orders of
magnitude) than can be achieved by IHC (up to 2 orders
of magnitude; 0–100% positive cells or H-score 0–300)
[21, 34]. An ongoing challenge in clinical management is
the decision whether to treat patients with luminal
breast cancer with systemic chemotherapy when other
clinicopathological factors, such as nodal status, are not
decisive [17]. Various multigene assays address exactly
this diagnostic dilemma. Oncotype DX® (Genomic Health,
Redwood City, CA, USA), MammaPrint® (Agendia, Irvine,
CA, USA), EndoPredict® (Myriad Genetics, Salt Lake City,
UT, USA), and Prosigna® (NanoString Technologies,
Seattle, WA, USA) provide risk scores with prognostic
information for distant recurrence in patients with lu-
minal A-like and luminal B-like (HER2-negative) breast
cancers. High and low risk scores, even though they are
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mainly prognostic, are frequently used to decide for or
against chemotherapy in the ER/PgR-positive, HER2-
negative subgroup [17]. Limitations exist, however, because
the appropriate course of action remains unclear for
patients with intermediate risk cancers or for node-
positive patients. Prospective studies on multigene tests
in breast cancer showing predictive values are limited
[35–37]. The randomized phase III Microarray in
Node-Negative and 1 to 3 Positive Lymph Node Disease
May Avoid Chemotherapy (MINDACT) trial recently
demonstrated that chemotherapy can be omitted in
around 46% of clinically high-risk cases with low Mamma-
Print® scores [37]. Similarly, the recurrence score mea-
sured with Oncoytpe DX® in the prospective randomized
phase III Plan B study demonstrated excellent 3-year sur-
vival by omitting chemotherapy in clinically high-risk but
recurrence score low-risk cases [35]. Further prospective
studies on Oncotype DX® testing revealed excellent 5-year
survival (98%) in low-risk score cases treated with hor-
mone therapy alone [36, 38]. However, these tests come
with high costs. In addition, some of these tests require
sending the samples to a central laboratory, such as
Oncotype DX® and MammaPrint®. In this respect, it is
interesting that a similar score, namely the immunohis-
tochemical 4 (IHC4) score, with comparable prognostic
value was generated by using just the four IHC markers
HER2, ER, PgR, and Ki67 [39, 40]. However, insufficient
standardization and considerable interlaboratory vari-
ability of IHC suggest that the IHC4 algorithm cannot
easily be transferred to other laboratories, although it
was successfully validated in an independent study co-
hort [41]. On the basis of data obtained in this study,
MammaTyper® could provide a highly reproducible and
reliable assessment of these four markers. It is tempting
to suggest that in the future a similar approach might
be applicable for the MammaTyper® to generate add-
itional prognostic information to guide personalized
treatment options at much lower cost than multigene
expression tests.
Conclusions
The MammaTyper® test has the potential to improve the
quality of primary breast cancer molecular diagnostics.
The test showed reliable reproducibility in the quantitative
assessment of the single markers ERBB2, ESR1, PGR, and
MKI67, as well as in the subtype determination, and
thereby overcomes the variability known on the basis
of diagnostic experience with IHC. The low intersite
and intrasite variance of the MammaTyper® test enables
pathology institutions to perform this assay in-house
and integrate the technology into routine diagnostic
services. However, additional clinical performance evalu-
ation studies in larger cohorts are necessary to confirm the
clinical utility of the test and to extract further predictive
information for more personalized clinical management of
patients with breast cancer.
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